StimCell Enegetics (STME) Stock Price

StimCell Enegetics Price

Munich·CLOSED
0.17
​
Market closed

Revenue at StimCell Enegetics has contracted by 26.2% per year over the past 9 years to 2,762.00 USD. For StimCell Enegetics, the net margin of -17,923.3% is down versus -962.9% a few years ago.

StimCell Enegetics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics business model & stock analysis

Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector.

Frequently asked questions about StimCell Enegetics

Converted at the current exchange rate, the StimCell Enegetics share trades at 0.15 EUR (0.17 USD).

The StimCell Enegetics share (STME) is listed on 2 stock exchanges, including: München (9CX.MU).

The revenue cannot currently be calculated for StimCell Enegetics.

The profit of StimCell Enegetics is -895,375.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of StimCell Enegetics is currently -3.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the StimCell Enegetics stock.

The P/S cannot be calculated for StimCell Enegetics currently.

The Eulerpool Quality Score for StimCell Enegetics is 2/10.

The ISIN of StimCell Enegetics is US15115X2062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of StimCell Enegetics is A12F27. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of StimCell Enegetics is STME. The ticker symbol is used to trade StimCell Enegetics shares on the stock exchange.

Fair ValueTerminal
0.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cellmedx.com
Currency
USD
Initial public offering
Mar 11, 2013
ISIN
US15115X2062
Cusip
15115X107
Sedol
BRJ9GD1
Market capitalization
3.51 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-8.30
P/Ee 2028
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
79.93 %
Last updated Oct 22, 2026, 7:13 PM

StimCell Enegetics Peer Group

StimCell Enegetics Ticker

MUNICH · 9CX.MUOTC · CMXC